How does spironolactone help treat PCOS?
LAST UPDATED: Aug 18, 2021
3 MIN READ
HERE'S WHAT WE'LL COVER
If you have polycystic ovary syndrome (PCOS) and struggle with excessive hair growth in unusual places, you’re not alone—up to 80% of people with PCOS experience this symptom (Spritzer, 2016). Spironolactone is one medication your healthcare provider may prescribe to combat this. Here's what you should know about spironolactone's role in the treatment of PCOS and if it could be an option for you.
What is spironolactone?
Spironolactone (brand name Aldactone) is a prescription diuretic—a type of medication that helps remove excess fluid from your body. Healthcare providers use spironolactone to treat several conditions, including heart failure, high blood pressure (hypertension) that doesn’t respond to other treatments, and fluid build-up from liver disease (Pfizer, 2018).
Spironolactone is also an anti-androgen, which means it blocks the effects of androgens (sometimes called male sex hormones, though they’re present in everyone), including testosterone (Sirmans, 2013).
How can spironolactone help treat PCOS?
Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women between puberty and menopause. PCOS is characterized by ovulation and menstrual dysfunction, infertility, and high androgen levels. Insulin resistance is also common, putting PCOS patients at increased risk of type 2 diabetes. Many people with PCOS struggle with obesity and can develop high blood pressure and high cholesterol (Escobar-Morreale, 2018).
A key component of PCOS is hyperandrogenism—abnormally high levels of androgens, including testosterone. Androgens are sometimes referred to as male sex hormones, but females also produce these hormones in small amounts. Elevated androgen levels contribute to many PCOS symptoms, including hirsutism (excess hair growth on the face, chest, and back), acne, and hair loss (Escobar-Morreale, 2018).
Spironolactone acts as an anti-androgen by blocking androgen receptors, including the receptors on hair follicles, which prevents testosterone from binding and exerting its hirsutism-causing effect. Spironolactone also decreases androgen production from the ovaries and adrenal glands (Sirmans, 2013).
Benefits and effectiveness of spironolactone
Spironolactone is primarily used to treat hirsutism in people with PCOS after other treatment options have failed (Sirmans, 2013). Hirsutism is when women experience excessive hair growth in a typical male pattern. Hair is thick, coarse, and dark and often grows on the chin, neck, lower face, and sideburns. Other body areas may also be affected, including the chest and back (Goodman, 2015).
Hormonal birth control is considered the first-line treatment for hirsutism in people with PCOS. Oral birth control pills (oral contraceptives), patches, or vaginal rings are all effective options. In addition to treating hirsutism, hormonal birth control also helps regulate menstrual cycles and improve acne (Legro, 2013). Because it can take at least six months to see a decrease in hair growth, many people also use other methods for removing unwanted hair, such as laser hair removal, waxing, or tweezing (Sirmans, 2013).
Unfortunately, not everyone responds fully to birth control. If you haven’t seen the results you were hoping for after six months, your healthcare provider may recommend adding spironolactone to your treatment plan (Sirmans, 2013). You may notice an improvement in your acne after starting spironolactone as well (Goodman, 2015).
Potential side effects and risks of spironolactone
Like any medication, spironolactone has the potential to cause side effects. Be sure to follow up with your healthcare provider if you experience any of the following (Goodman, 2015; Patibandla, 2021):
Irregular periods (unlikely to occur if you’re also taking birth control)
Spironolactone can affect the levels of different electrolytes in your body, particularly potassium (Pfizer, 2018). Very high levels of potassium can cause heart rhythm problems (Hunter, 2019).
You may be at increased risk of developing high potassium levels with spironolactone if you (Hunter, 2019):
have kidney problems
take other medications that increase potassium levels, like ACE-inhibitors (ex. lisinopril) or ARBs (ex. valsartan)
take potassium supplements or use potassium-containing salt substitutes
Your healthcare provider will likely monitor your potassium levels after starting spironolactone to ensure they don’t become too high.
Spironolactone can cause birth defects, preventing the proper development of sex organs in male babies if taken during pregnancy. It is recommended that you take birth control while on spironolactone to ensure you do not become pregnant (Goodman, 2015). If you are planning on becoming pregnant, tell your healthcare provider so they can find a treatment that will be more appropriate for you.
Spironolactone is available in doses of 25, 50, and 100 mg tablets, as well as an oral liquid if you have trouble swallowing pills (CMP Pharma, 2017; Pfizer, 2018).
The starting dose for the treatment of hirsutism is 50 mg twice per day. Your healthcare provider may increase your dose, depending on your symptoms, up to 100 mg twice per day (Goodman, 2015).
If your PCOS symptoms are affecting your physical appearance, you may feel uncomfortable or struggle with self-confidence. Don’t hesitate to discuss any concerns with your healthcare provider. Effective treatment options, including spironolactone, are available. Your healthcare provider will likely recommend a combination of medications, lifestyle modifications, and weight loss to help target all of your PCOS symptoms and get you feeling your best.
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
CMP Pharma, Inc. (2017). Highlights of prescribing information: Carospir. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209478s000lbl.pdf
Escobar-Morreale H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews. Endocrinology, 14 (5), 270–284. doi: 10.1038/nrendo.2018.24. Retrieved from https://pubmed.ncbi.nlm.nih.gov/29569621/
Goodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., Carmina, E., et al. (2015). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 21 (11), 1291–1300. doi: 10.4158/EP15748.DSC. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26509855/
Hunter, R. W., & Bailey, M. A. (2019). Hyperkalemia: pathophysiology, risk factors and consequences. Nephrology, Dialysis, Transplantation. 34( Suppl 3), iii2–iii11. doi: 10.1093/ndt/gfz206. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31800080/
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., Welt, C. K., & Endocrine Society (2013). Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 98 (12), 4565–4592. doi: 10.1210/jc.2013-2350. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399492/
Patibandla, S., Heaton, J., & Kyaw, H. (2021). Spironolactone. In StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK554421/
Pfizer. (2018). Highlights of prescribing information: Aldactone. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf
Sirmans, S. M., & Pate, K. A. (2013). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology, 6, 1–13. doi: 10.2147/CLEP.S37559. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24379699/
Spritzer, P. M., Barone, C. R., & Oliveira, F. B. (2016). Hirsutism in polycystic ovary syndrome: pathophysiology and management. Current Pharmaceutical Design, 22 (36), 5603–5613. doi: 10.2174/1381612822666160720151243. Retrieved from https://pubmed.ncbi.nlm.nih.gov/27510481/